To read the full story, subscribe or sign in.

Okogen begins phase II trial in Australia with topical ranpirnase to fight adenoviral conjunctivitis

Aug. 14, 2019

PERTH, Australia – San Diego-based Okogen Inc. is taking its clinical trial program to Australia where it will test its lead compound OKG-0301 for acute adenoviral conjunctivitis in the phase II (RUBY) trial.

BioWorld Asia Clinical

NIH changes set industry up for workforce, ideas drought

BioWorld

On March 1, 2025, former NIH director Francis Collins’ announced that he had fully resigned from the NIH, where he continued to lead a laboratory after his...

Today's news in brief

BioWorld

BioWorld briefs for March 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for March 12, 2025

Hummingbird migrates ADCs, tech to newco Callio’s $187M debut

BioWorld

Antibody-drug conjugate (ADC)-focused Callio Therapeutics debuted on March 3 with the closing of a $187 million series A financing round based on cancer drug...

At CROI, HIV cure trials raise hopes for broader applicability

BioWorld

At the 2025 meeting of the Conference on Retroviruses and Opportunistic Infections (CROI) it was the best of times, it was the worst of times. On the first full...